Welcome to our dedicated page for CytomX Therapeutics SEC filings (Ticker: CTMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CytomX Therapeutics filings document a Delaware clinical-stage oncology biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under CTMX. Recent 8-K reports furnish quarterly and annual financial results, business updates, clinical-program disclosures for Varseta-M and other PROBODY programs, and clinical safety reporting tied to the company’s development studies.
Its formal records also cover capital structure and financing activity, including a completed public offering of common stock and pre-funded warrants made through a Form S-3 registration framework. Proxy materials describe board elections, auditor ratification, authorized-share amendments, equity incentive plan matters, executive compensation, and stockholder voting procedures.
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen report passive ownership of CytomX Therapeutics, Inc. common stock on an amended Schedule 13G. As of the close of business on June 30, 2026, they report beneficial ownership of 7,811,033 shares of common stock, representing 3.6% of the class, with no shares held directly. Voting and investment power over these shares is shared through an investment fund managed by Point72 Asset Management, with Point72 Capital Advisors as its general partner and Mr. Cohen controlling both entities. The filing states this ownership is now at or below five percent of the class and disclaims that the reporting persons are beneficial owners for certain legal purposes.
Kynam Capital Management, LP, together with Kynam Capital Management GP, LLC and Yue Tang, reports beneficial ownership of CytomX Therapeutics, Inc. common stock. The group has shared voting and dispositive power over 21,703,093 shares, representing 9.96% of the outstanding common stock, with no sole voting or dispositive power reported by any of the filers.
State Street Corporation reports beneficial ownership of CytomX Therapeutics, Inc. common stock. State Street holds 11,747,236 shares of common stock, representing 5.4% of the class. All of these shares are reported with shared voting power of 11,471,693 shares and shared dispositive power of 11,747,236 shares, with no sole voting or dispositive power.
The position is held through asset management subsidiaries including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd. No other person is identified as having rights to more than 5% of the class through this holding.
CytomX Therapeutics reported Q2 2026 total revenue of $1.4 million, down from $18.7 million a year earlier, as prior collaboration obligations with Bristol Myers Squibb and Astellas wound down. Total operating expenses rose to $25.2 million from $19.9 million, leading to a net loss attributable to common stockholders of $20.7 million versus a net loss of $0.2 million in Q2 2025.
The company ended June 30, 2026 with $330.3 million in cash, cash equivalents and investments and expects this to fund operations to at least the second half of 2028; this excludes a $37.0 million target selection payment received in July from Regeneron under an expanded bispecific immunotherapy collaboration that allows for up to approximately $4.0 billion in potential milestones. CytomX advanced its varsetatug masetecan (Varseta‑M) colorectal cancer program toward a planned first registrational study in the first half of 2027, broadened monotherapy and combination trials into additional gastrointestinal tumors, and continued early-stage development of CX‑801 in advanced melanoma.
CytomX Therapeutics, Inc. reported Q2 2026 revenue of $1.4 million, down from $18.7 million a year earlier, and a net loss of $20.7 million versus a $0.2 million loss, as large 2025 collaboration revenues from partners such as Bristol Myers Squibb and Astellas were not repeated.
For the first half of 2026, revenue was $11.7 million and the net loss $38.9 million, compared with $69.6 million of revenue and $23.4 million of net income in 2025. Operating expenses rose to $55.1 million from $48.2 million, with higher research and development and general and administrative costs including increased stock‑based compensation.
Liquidity strengthened: at June 30, 2026 cash and cash equivalents were $17.2 million and short‑term U.S. Treasury investments $313.1 million, aided by approximately $234.2 million of net proceeds from a March underwritten equity and pre‑funded warrant offering. Deferred revenue increased to $54.7 million, supported by an expanded Regeneron collaboration that added two new bispecific programs, a $37.0 million upfront payment and potential milestones aggregating up to about $4.0 billion. Varseta‑M showed Phase 1 activity in late‑line metastatic colorectal cancer with confirmed response rates up to 32% and median progression‑free survival up to 7.1 months, and CytomX is preparing registrational planning, combination studies and expansion into additional EpCAM‑expressing tumors, while CX‑801 continues Phase 1 development with Merck’s KEYTRUDA.
CytomX Therapeutics, Inc. granted Chief Legal Officer Alejandra Carvajal 450,000 stock options on August 3, 2026, with an exercise price of 3.1700 per share and expiration on August 2, 2036. The options vest 25% after one year from August 3, 2026, then monthly over four years, subject to continued service.
On the same date, Carvajal also received 100,000 restricted stock units (RSUs), each settling into one share of common stock upon vesting. These RSUs vest 25% annually each September 15, starting September 15, 2027, contingent on continued service. Following these awards, she holds 450,000 options and 100,000 RSUs directly.
CytomX Therapeutics, Inc. reports that its Chief Legal Officer, Alejandra Carvajal, has become a reporting insider by filing a Form 3 insider ownership report. No transactions in CytomX securities are reported in this filing, and an attached Exhibit 24.1 provides a Power of Attorney for future Section 16-related actions.
Bank of America Corporation filed a Schedule 13G reporting beneficial ownership of CytomX Therapeutics, Inc. common stock. It reports beneficial ownership of 15,134,689 shares, representing 7.0% of the outstanding common stock, based on 217,702,919 shares outstanding as reported by CytomX as of April 30, 2026.
Bank of America reports no sole voting or dispositive power. It has shared voting power over 15,133,689 shares and shared dispositive power over 15,134,689 shares through its wholly owned subsidiaries, including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, and Merrill Lynch Pierce Fenner & Smith, Inc.
CytomX Therapeutics director Charles S. Fuchs received a grant of stock options covering 118,000 shares of common stock, with an exercise price of $3.24 per share and an expiration date of July 23, 2036. 1/36th of the shares vest on each monthly anniversary starting July 24, 2026, so all options vest over three years, subject to his continued service.
CytomX Therapeutics, Inc. has an initial Form 3 statement for Charles S. Fuchs, identifying him as a director of the company. The statement reports no share purchases, sales, or derivative exercises and references Exhibit 24.1 – Power of Attorney authorizing representation in ownership reporting matters.